$MMSI (Merit Medical Systems, Inc.)

$MMSI {{ '2016-07-27T15:13:12+0000' | timeago}} • Announcement

$MMSI said it appointed David Liu to serve as a director. Liu holds the current appointment of Clinical Associate Professor, Faculty of Medicine, at University of British Columbia and is in active clinical practice, with board certification in both Canada and the United States.

$MCK {{ '2017-07-21T16:07:44+0000' | timeago}} • Announcement

Biologics, a unit of healthcare technology firm $MCK, said it will join the limited distribution network of $PBYI to promote the latter’s kinase inhibitor Nerlynx. The formulation is indicated for treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer.

$AGN {{ '2017-07-19T15:54:53+0000' | timeago}} • Announcement

$AGN appointed Joseph Boccuzi to its BoD, effective immediately. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with the global executive search and leadership consulting firm.

$BDX {{ '2017-07-19T13:58:34+0000' | timeago}} • Announcement

$BDX received 510(k) clearance from the FDA for the BD FACSLyric flow cytometer system, an easy-to-use in vitro diagnostic (IVD) system, for use with BD Multitest assays for immunological assessment of individuals and patients having or suspected of having immune deficiency.

$GS {{ '2017-07-19T11:22:37+0000' | timeago}} • Webcast

$GS advised a number of important transactions that were announced during 2Q17, including $BCR's $24Bil sale to $BDX. $AMZN's $13.7Bil acquisition of $WFM, and $DFT's $7.6Bil merger with $DLR.

$BAX {{ '2017-07-18T14:01:55+0000' | timeago}} • Announcement

The BoD of $BAX declared a quarterly dividend of $0.16 per share of its common stock. The dividend is payable on Oct 2, 2017, to stockholders of record as of Sept 1, 2017.

$BAX {{ '2017-07-17T20:58:53+0000' | timeago}} • Announcement

$BAX appointed Cathy Smith, EVP and CFO of $TGT, to its BoD, bringing the total number of directors serving the company at this time to 13. Smith now also serves on $BAX's Audit Committee.

$AMGN {{ '2017-07-13T12:24:26+0000' | timeago}} • Announcement

$AMGN and $AGN announced they will discuss data supporting the ABP 215 Biologics License Application (BLA) with FDA's Oncologic Drugs Advisory Committee. ABP 215 is a biosimilar candidate to Avastin (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.

$LIVN {{ '2017-07-12T12:45:32+0000' | timeago}} • Announcement

$LIVN appointed Keyna Skeffington as SVP and General Counsel. Skeffington most recently served as Vice President of Legal – Corporate and Securities, Deputy General Counsel and Assistant Secretary at $MDT.

$AGN {{ '2017-07-10T16:14:16+0000' | timeago}} • Announcement

$AGN announced additional results of a prespecified prospective pooled subgroup analysis from the two Phase 3 studies, which evaluated the efficacy and safety of Viberzi to treat the symptoms associated with irritable bowel syndrome with diarrhea, abdominal pain and diarrhea.

$MDT {{ '2017-07-10T15:43:07+0000' | timeago}} • Announcement

$MDT announced the expanded FDA approval of the self-expanding CoreValve Evolut transcatheter aortic valve replacement platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery.

$MASI {{ '2017-06-30T12:41:36+0000' | timeago}} • Announcement

Medical technology firm $MASI entered into a partnership with Midmark Corp. for enhancing the accuracy and efficiency of vital signs acquisition in the clinical space. Under the deal, Masimo’s SET pulse oximetry technology is an available option with Midmark's IQvitals Zone. The combination provides accurate and real-time vital signs information.

$LIVN {{ '2017-06-29T15:56:55+0000' | timeago}} • Announcement

$LIVN received FDA approval of its VNS Therapy system in patients as young as four years of age with partial onset seizures that are refractory to antiepileptic medications.

$AGN {{ '2017-06-27T13:15:55+0000' | timeago}} • Announcement

Pharma company $AGN launched Refresh Optive Mega-3, an over-the-counter artificial tear under the company’s Refresh portfolio. The formulation protects tears from evaporating while nourishing the damaged lipid layer and providing essential hydration to the tear film layers in patients suffering from ‘dry eye’.

$BAX {{ '2017-06-26T13:13:55+0000' | timeago}} • Announcement

$BAX has announced a bi-directional integration between its software solution DoseEdge Pharmacy Workflow Manager and the Epic Willow Inpatient Pharmacy System. The integration will help hospitals efficiently comply with requirements from the Centers for Medicare and Medicaid Services and other insurers.

$MDT {{ '2017-06-23T12:04:14+0000' | timeago}} • Announcement

$MDT has announced a 7% increase in its quarterly cash dividend, raising the amount to $0.46 per ordinary share. The dividend is payable on July 26, 2017, to shareholders of record as of July 7, 2017.

$MMSI {{ '2017-06-22T16:08:44+0000' | timeago}} • Announcement

$MMSI received 513(f)(2) (de novo) classification from the FDA to expand indication for $MMSI's Embosphere Microspheres. The indication now includes prostatic artery embolization (PAE) for symptomatic benign prostatic hyperplasia (BPH).

$LIVN {{ '2017-06-21T14:06:24+0000' | timeago}} • Announcement

$LIVN said its latest VNS Therapy systems received FDA approval for expanded MRI labeling, affirming VNS Therapy as the only epilepsy device approved by the FDA for MRI scans. This ensures VNS patients with latest technology may visit any MRI center in US and have access to more than 90% of scans routinely performed on patients with epilepsy.

$MDT {{ '2017-06-20T13:54:51+0000' | timeago}} • Announcement

$MDT said data from a recent study showed that its cardiac resynchronization therapy devices reduced healthcare system costs and improved therapy delivery in heart failure patients. A European health-economic analysis indicated that Medtronic’s AdaptivCRT extended life expectancy of patients by about four months, while lowering healthcare costs.

$SYK {{ '2017-06-19T12:28:25+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ. The transaction is expected to be dilutive to $SYK's 2017 adjusted EPS by $0.03-0.05. There is no change in $SYK's 2017 adjusted EPS forecast of $6.35-6.45. For 2018, this transaction is expected to be neutral to $SYK's earnings and accretive thereafter.

$SYK {{ '2017-06-19T12:26:47+0000' | timeago}} • Announcement

$SYK agreed to buy $NVDQ for $11.75 per share, or $701MM with a net purchase price of $654MM, reflecting net cash of about $47MM. The transaction is expected to close at the end of 3Q17.

Recent Transcripts

NURO (NeuroMetrix Inc.)
Thursday, July 20 2017 - 12:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
NXTM (Nxstage Medical, Inc.)
Tuesday, May 9 2017 - 1:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
OFIX (Orthofix International N.V.)
Thursday, May 4 2017 - 8:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
TFX (Teleflex Incorporated)
Thursday, May 4 2017 - 12:00pm
BDX (Becton, Dickinson and Company)
Thursday, May 4 2017 - 12:00pm
WMGI (Wright Medical Group N.V.)
Wednesday, May 3 2017 - 8:30pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
LIVN (LivaNova PLC)
Wednesday, May 3 2017 - 1:00pm
BDX (Becton, Dickinson and Company)
Tuesday, May 2 2017 - 12:00pm
MMSI (Merit Medical Systems, Inc.)
Thursday, April 27 2017 - 9:00pm
SPNC (The Spectranetics Corporation)
Thursday, April 27 2017 - 8:30pm
SRDX (SurModics, Inc.)
Thursday, April 27 2017 - 12:30pm
CRY (CryoLife Inc.)
Thursday, April 27 2017 - 12:00pm
BAX (Baxter International Inc.)
Wednesday, April 26 2017 - 12:30pm
SYK (Stryker Corporation)
Tuesday, April 25 2017 - 8:30pm

AlphaGraphics you may like